Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471129 | 1.00 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471314 | 0.93 | MEN1 (0.54) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL6337999 | 0.92 | FAAH (0.53) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471831 | 0.86 | LMNA (0.59) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471857 | 0.86 | MEN1 (0.51) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471856 | 0.86 | LMNA (0.59) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471657 | 0.85 | MAPT (0.54) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1473349 | 0.85 | MAPT (0.57) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471071 | 0.84 | GAA (0.48) | MEN1KMT2ALMNAMAPTCACNA1B | |
| SCHEMBL1471161 | 0.83 | MAPT (0.50) | MEN1KMT2ALMNAMAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | MEN1 1535/4885KMT2A 4798/4885LMNA 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.